NCT06160401View on ClinicalTrials.gov

Evaluation of Safety, Tolerability, PK/PD, and Metabolism of Single-Dose Singletine(DC407) in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

January 30, 2021

Study Completion Date

January 30, 2021

Conditions
Healthy Subjects
Interventions
DRUG

Singletine

Singletine orally administered

DRUG

Placebo

Placebo orally administered

Trial Locations (1)

200020

Shanghai Xuhui District Central Hospital, Shanghai

All Listed Sponsors
lead

Guangzhou JOYO Pharma Co., Ltd

INDUSTRY

NCT06160401 - Evaluation of Safety, Tolerability, PK/PD, and Metabolism of Single-Dose Singletine(DC407) in Adults | Biotech Hunter | Biotech Hunter